Jobs
-
Mylan has announced that its subsidiary Mylan Specialty (formerly Dey Pharma) has reached an agreement with Sunovion Pharmaceuticals (formerly Sepracor) in which Sunovion “has acknowledged that two Mylan patents are valid, enforceable and infringed by… Read more . . .
-
According to Sun Pharma, the FDA has approved an Abbreviated New Drug Application (ANDA) for a generic version of azelastine nasal spray submitted by a Sun subsidiary. Sun notes that the US sales of azelastine… Read more . . .
-
“Under the ‘ordinary consumer’ standard, a product designed for intranasal use is expected not to cause irreparable injury to the nose if used in a foreseeable manner,” said U.S. District Judge William Alsup in his… Read more . . .
-
Swedish contract developer and manufacturer Recipharm says that it has borrowed €90 million from Swedbank AB in order to finance additional contract pharmaceutical manufacturing capacity and acquisitions. The company says that it also plans to… Read more . . .
-
Boehringer Ingelheim has presented data from studies of olodaterol and tiotropium at the 2012 Annual Meeting of the American Thoracic Society. According to the company, it has now completed its Phase 2 trials of olodaterol,… Read more . . .
-
Inhaled drug developer Prosonix has announced the second closing of its Series B equity financing round, which was extended to £17.1M. A new investor, Gimv, added £5.7M to the funds from original syndicate members Ventech,… Read more . . .
-
Part 2 of our discussion on worldwide MDI manufacturing. Read more . . . . Read more . . .
-
Particle characterization specialist Gateway Analytical is offering two upcoming webinars of interest to OINDP developers, manufacturers, and quality assurance personnel. The first of the webinars, Ensure Quality Inhalation Products with Wear Debris Analysis of Medical… Read more . . .
-
Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology.… Read more . . .
-
The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA